| --- | --- | --- | --- | --- | --- | --- | |-------------|-------|-------|-------------------------|-----------------------------------------------------|-----------|-------| | | | | | | | | | | | | | | | | | 3 Q 2 0 2 | 4 | | E A R N I N G S C A L L | Reaching Patients Through \| O c t o b e r 3 1 | , 2 0 2 4 | | | | | | | Immunology Innovation | | | | | | | | | | | Forward Looking Statements This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and n ...

October 24, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 31, 2024 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2024 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/inv ...

VYVGART and VYVGART Hytrulo Efficacy and Safety - VYVGART demonstrates rapid, deep, and sustained responses in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [4] - More than 50% of gMG patients show substantial and sustained reduction in steroid use after VYVGART initiation [1] - VYVGART Hytrulo shows sustained functional benefit in motor function and muscle strength in CIDP patients, regardless of prior treatment [5] - VYVGART has a consistent and favorable safety profile with over 8,000 patient years of safety data [6] Real-World Data and Clinical Studies - Real-world data show 55% of gMG patients reduced corticosteroid use by ≥5 mg/day one year post VYVGART initiation [5] - 42% of gMG patients achieved steroid doses of ≤5mg/day after one year of VYVGART treatment [5] - Phase 3 studies are ongoing for seronegative and ocular MG populations, showing consistent and clinically meaningful improvements [5] Pipeline Expansion in Neurology - argenx is advancing empasiprubart for multifocal motor neuropathy (MMN) and ARGX-119 for amyotrophic lateral sclerosis (ALS) and congenital myasthenic syndromes (CMS) [9] - Phase 2 ARDA study shows empasiprubart reduces IVIg retreatment risk by 91% and improves grip strength in MMN patients [10] - A Phase 3 study of empasiprubart in MMN is set to start by the end of 2024 [10] Immunology Pipeline Highlights - argenx is evaluating empasiprubart in multiple autoimmune indications, including delayed graft function, dermatomyositis, and CIDP [32] - ARGX-119, a muscle-specific kinase (MuSK) agonist, is being developed for neuromuscular diseases [34] - The company continues to expand its neurology pipeline to deliver transformative outcomes for patients [3] Market and Regulatory Position - VYVGART is the first approved FcRn blocker in the US, EU, China, and Canada for gMG treatment [28] - VYVGART Hytrulo is the first-and-only approved FcRn blocker administered by subcutaneous injection [29] - argenx is committed to improving the lives of patients with severe autoimmune diseases through its immunology pipeline [38]

After grappling with recession fears, the Federal Reserve’s jumbo interest rate cuts helped the broader S&P 500 to defy the odds of a notorious September and notch record highs. The S&P 500 posted its best three-quarters of the 21st century, and if history is any guide, the index is well-poised to continue its winning streak over the next three months. The 30-stock Dow and the tech-laden Nasdaq also closed in the green in the first nine months of 2024. Thus, it’s judicious for astute investors to place thei ...

I specialize in biotech and healthcare investment analysis, integrating clinical expertise with a solid foundation in business strategy. My approach leverages detailed risk-return charts and DCF analyses to clearly communicate the investment potential and associated risks. I advocate for a barbell portfolio strategy, with 90% allocated to secure assets such as Treasuries and broad-market ETFs, and 10% to high-alpha stocks. This balanced approach ensures that all recommendations are made within a context of ...

Core Insights - The ADHERE Study is the largest and most innovative clinical trial for chronic inflammatory demyelinating polyneuropathy (CIDP) published in The Lancet Neurology, demonstrating significant clinical improvements with VYVGART® Hytrulo [2][4] Company Overview - Argenx SE is a global immunology company focused on improving the lives of patients with severe autoimmune diseases, with VYVGART Hytrulo being a key product for treating CIDP [2][3] Product Information - VYVGART Hytrulo is the first and only FDA-approved neonatal Fc receptor (FcRn) blocker for CIDP, showing a 61% reduction in relapse risk and rapid onset of action [4][5][12] - The product combines efgartigimod alfa and hyaluronidase-qvfc, facilitating subcutaneous injection delivery of biologics [12] Clinical Trial Highlights - The ADHERE trial involved 322 adult patients, demonstrating a 69% clinical improvement rate and a 99% participation rate in the open-label extension [4][10] - The primary endpoint was met with a significant reduction in relapse risk (HR: 0.39, p<0.0001) and disease progression [4][10] Disease Context - CIDP is a rare autoimmune disease affecting the peripheral nervous system, with approximately 24,000 patients in the U.S. currently receiving treatment [13]

argenex SE (ARGX) shares rallied 4% in the last trading session to close at $548.49. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.1% gain over the past four weeks.The stock rallied as optimism grew over the company’s marketed product, Vyvgart Hytrulo (efgartigimod), which is approved for treating adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has argenex SE (ARGX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.argenex SE is a member of the Medical sector. This group includes 1019 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank gauges the strength ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 31:argenx SE (ARGX) : This biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 56.2% over the last 60 days.argenx's shares gained 32.9% over the last three months compared with the S&P 500’s advanced of 8.4%. The company possesses a Momentum Score of A.Vizsla Silver Corp. (VZLA) : This mineral exploration company has a Zacks R ...

argenex SE (ARGX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a cha ...